Income Tax Expense (Benefit) in USD of Centessa Pharmaceuticals plc from 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Centessa Pharmaceuticals plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2019 to Q3 2025.
  • Centessa Pharmaceuticals plc Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $166K, a 72.7% decline year-over-year.
  • Centessa Pharmaceuticals plc Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $3.39M, a 15.4% increase year-over-year.
  • Centessa Pharmaceuticals plc annual Income Tax Expense (Benefit) for 2024 was $2.84M.
  • Centessa Pharmaceuticals plc annual Income Tax Expense (Benefit) for 2023 was -$25.1M, a 3254% decline from 2022.
  • Centessa Pharmaceuticals plc annual Income Tax Expense (Benefit) for 2022 was -$747K, a 755% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

Centessa Pharmaceuticals plc Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $3.39M $166K -$442K -72.7% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $3.83M $778K +$73K +10.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $3.76M $1.4M +$916K +190% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $2.84M $1.05M -$94K -8.22% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-24
Q3 2024 $2.94M $608K +$3.43M Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 -$496K $705K +$24.8M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 -$25.3M $481K -$196K -29% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 -$25.1M $1.14M +$1.81M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-24
Q3 2023 -$26.9M -$2.83M -$2.69M -1904% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$24.2M -$24.1M -$24M -109223% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$150K $677K +$597K +746% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$747K -$664K -$778K -682% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $31K -$141K -$141K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $172K -$22K -$22K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $194K $80K +$80K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $114K $114K +$114K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 $0 $0 $0 Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $0 $0 Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $0 Jan 30, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $0 Jan 1, 2021 Jan 29, 2021 10-K 2023-03-30
Q3 2020 $0 Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15

Centessa Pharmaceuticals plc Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $2.84M +$27.9M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-24
2023 -$25.1M -$24.3M -3254% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-24
2022 -$747K -$861K -755% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $114K +$114K Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $0 $0 Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
2019 $0 Jan 1, 2019 Dec 31, 2019 10-K 2022-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.